Last reviewed · How we verify
Comparator: celecoxib
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
At a glance
| Generic name | Comparator: celecoxib |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Celecoxib is a selective COX-2 inhibitor that preferentially blocks COX-2 over COX-1, thereby reducing inflammatory prostaglandins while theoretically sparing the protective prostaglandins produced by COX-1 in the gastrointestinal tract. This selectivity was designed to provide anti-inflammatory and analgesic efficacy with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Familial adenomatous polyposis (FAP)
Common side effects
- Dyspepsia
- Abdominal pain
- Diarrhea
- Headache
- Hypertension
- Cardiovascular events (myocardial infarction, stroke)
Key clinical trials
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED) (PHASE3)
- A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED) (PHASE3)
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib (PHASE1)
- Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis (PHASE3)
- Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (PHASE3)
- Clinical Trial of YYC301 P3 for Treatment of Osteoarthritis of the Knee (PHASE3)
- Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: celecoxib CI brief — competitive landscape report
- Comparator: celecoxib updates RSS · CI watch RSS
- Organon and Co portfolio CI